Therma Bright Initiates Data Collection With AI Digital Cough Technology App at TB Clinics
Therma Bright Initiates Data Collection With AI Digital Cough Technology App at TB Clinics
Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has established collaborations with several Tuberculosis (TB) medical care facilities to initiate the data collection and screening of active respiratory challenged patients.
安大略省多倫多--（Newsfile Corp.——2023年5月10日）——Therma Bright Inc.（多倫多證券交易所股票代碼：THRM）（OTCQB：TBRIF）（“THERMA” 或 “公司”）是各種前沿專有診斷和醫療器械技術的開發商和投資者，欣然宣佈，該公司已與多家結核病（TB）醫療機構建立了合作關係，以啓動活性肺結核（TB）的數據收集和篩查呼吸障礙患者。
The potential for a non-invasive, non-sputum-based and point-of-care mobile app holds significant promise for efficiently triaging and aiding health care professionals to make an informed decision on respiratory issues in developed and underdeveloped parts of the world.
非侵入性、非痰液和即時護理移動應用程序的潛力爲有效分診和幫助世界發達和欠發達地區的醫療保健專業人員就呼吸問題做出明智的決定帶來了巨大希望。
Current practices for screening respiratory issues, such as TB, are time consuming and include; chest X rays, skin tests and blood tests. These tests are typically inaccessible to many deserving and developing nations around the world. Therma Bright's licensed Digital Cough Technology ("DCT"), from AI4LYF, offers a tremendous opportunity for Therma Bright and these communities to lead the way; bringing innovative AI-driven, real-life validated digital collection, screening and user-friendly technology to the global marketplace.
目前篩查肺結核等呼吸道問題的做法非常耗時，包括：胸部 X 光檢查、皮膚檢查和血液檢查。這些測試通常是世界上許多當之無愧的發展中國家無法獲得的。來自 AI4LYF 的 Therma Bright 授權的數字咳嗽技術（“DCT”）爲 Therma Bright 和這些社區提供了引領潮流的絕佳機會；爲全球市場帶來了由人工智能驅動、經過現實生活驗證的創新型數字採集、篩選和用戶友好型技術。
Long before COVID-19, communities around the world have struggled to address the increase in respiratory ailments within their area, including Tuberculosis ("TB") - which is a global threat and found in every country around the world. In fact, TB causes over one million deaths annually. The World Health Organization (WHO) estimates that 1.8 billion people-close to one quarter of the world's population-are infected with Mycobacterium tuberculosis (M.tb), the bacteria that causes TB. Last year, 10.6 million contracted TB and 1.6 million died.
早在 COVID-19 之前，世界各地的社區就一直在努力應對所在地區內呼吸系統疾病的增加，包括結核病（“TB”），結核病是一種全球威脅，存在於世界每個國家。事實上，結核病每年造成超過一百萬人死亡。世界衛生組織（WHO）估計，有18億人（接近世界人口的四分之一）感染了 結核分枝桿菌 （m.tb），導致結核病的細菌。去年，有1,060萬人感染了結核病，160萬人死亡。
Therma Bright has embarked on this digital collection effort with its licensing partner, AI4LYF, with the goal of securing cough data via its innovative AI-driven DCT App. The data collected will be in partnership with several hospitals across Pakistan, a nation where TB has reached a concerning public health threat.
Therma Bright 已開始與其許可合作伙伴 AI4LYF 一起開展這項數字收集工作，目標是通過其創新的人工智能驅動的 DCT 應用程序保護咳嗽數據。收集的數據將與巴基斯坦的幾家醫院合作進行，結核病已成爲令人擔憂的公共衛生威脅。
"The goals of the WHO's End Tuberculosis strategy, which aims to achieve a 90% reduction in TB incidence and a 95% reduction in TB mortality by 2035, will not be achieved without new, AI- driven innovative solutions," shared Dr. Ali Riswan, CEO of AI4LYF. "These new, and innovative solutions and tools offer communities, like those in Pakistan, an improved point of care (POC) screening and monitoring solution at the most decentralised levels of patient care - a community's health system. AI4LYF, in partnership with Therma Bright, can make a significant impact by developing and deploying Therma Bright's DCT screening App. "
AI4LYF 首席執行官阿里·里斯旺博士表示：“世衛組織終結結核戰略的目標是到2035年將結核病發病率降低90％，將結核病死亡率降低95％，如果沒有新的人工智能驅動的創新解決方案，就無法實現。”“這些新的創新解決方案和工具爲像巴基斯坦這樣的社區在最分散的患者護理層面——社區衛生系統——提供了更好的醫療點（POC）篩查和監測解決方案。AI4LYF 與 Therma Bright 合作，可以通過開發和部署 Therma Bright 的 DCT 篩查應用程序產生重大影響。“
Therma Bright and AI4LYF are currently working with these TB medical care facilities to begin the digital data collection from their most active patients.
Therma Bright 和 AI4LYF 目前正在與這些結核病醫療機構合作，開始從最活躍的患者那裏收集數字數據。
"This data collection effort will allow us to match medical histories, patient vitals, acoustic cough samples and other salient data points from active TB patients, which will eventually help us create one of the most valuable databases in the world for respiratory illness research," shared Rob Fia, CEO of Therma Bright. "This effort offers a route to help expedite the deployment of a new innovative App to screen and monitor TB and other respiratory illnesses, which ultimately will save communities time, money and lives."
Therma Bright首席執行官Rob Fia表示：“這項數據收集工作將使我們能夠匹配來自活躍結核病患者的病史、患者生命體徵、咳嗽樣本和其他重要數據點，這最終將幫助我們創建世界上最有價值的呼吸系統疾病研究數據庫之一。”“這項工作爲加快部署新的創新應用程序提供了途徑，用於篩查和監測結核病和其他呼吸系統疾病，最終將爲社區節省時間、金錢和生命。”
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
關於 Therma Bright Inc
Therma Bright是各種前沿專有診斷和醫療設備技術的開發商和合作夥伴，致力於爲消費者和醫療專業人員提供優質、創新的解決方案，以應對當今一些最重要的醫療和醫療保健挑戰。Therma Bright Inc. 在多倫多證券交易所（多倫多證券交易所股票代碼：THRM）（OTCQB：TBRIF）（FSE：JNX）上市。訪問：。
About AI4LYF:
AI4LYF is an innovative smart-health company with a mission to transform lives through deep intelligence. Having pioneered DCT, it is also working on AI based novel solutions that have potential to change the "Reactive Sick care" into "predictive, preventive, personalized health care" for fuller and longer lives for all.
關於 AI4LYF：
AI4LYF 是一家創新的智能健康公司，其使命是通過深度智能改變生活。作爲DCT的先驅，它還在研究基於人工智能的新型解決方案，這些解決方案有可能將 “反應性疾病護理” 轉變爲 “預測性、預防性、個性化醫療保健”，爲所有人提供更充實、更長的壽命。
Therma Bright and AI4LYF are excited to explore numerous use cases that DCT can offer beyond COVID-19 including other respiratory diseases. One immediate use case is to scale DCT as public health platform for anytime, anywhere screening for infectious (and non-infectious) respiratory diseases. Their joint vision is to leverage this collaboration as a progressive journey in the development of much-needed smart healthcare solution for humanity and prevention and preparedness for future pandemics.
Therma Bright 和 AI4LYF 很高興探索 DCT 除了 COVID-19 之外還能提供的衆多用例，包括其他呼吸系統疾病。一個直接的用例是將DCT擴展爲公共衛生平臺，用於隨時隨地篩查傳染性（和非傳染性）呼吸道疾病。他們的共同願景是利用此次合作，逐步開發人類急需的智能醫療解決方案，預防和防範未來的疫情。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright公司
首席執行官 Rob Fia
rfia@thermabright.com
Follow us on Twitter
在推特上關注我們
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性陳述
本新聞稿中的某些陳述構成 “前瞻性” 陳述。這些聲明與未來的事件有關，例如快速 COVID-19 病毒檢測和相關儀器的開發和商業化。如新聞稿所述。所有這些陳述都涉及大量已知和未知的風險、不確定性和其他因素，這些因素可能導致實際結果與此類前瞻性陳述所表達或暗示的結果有所不同。前瞻性陳述涉及重大風險和不確定性，不應將其視爲未來業績或業績的保證，也不一定能準確表明是否會取得此類結果。由於多種因素和風險，實際結果可能與預期的結果存在重大差異。儘管本新聞稿中包含的前瞻性陳述基於本新聞稿發佈之日公司管理層認爲的合理假設，但公司無法向投資者保證實際業績將與這些前瞻性陳述一致。本新聞稿中包含的前瞻性陳述自本文發佈之日起作出，除非適用的證券法規要求，否則公司不打算或有義務更新或修改任何前瞻性陳述，無論是由於新信息、未來事件還是其他原因。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所風險投資交易所及其監管服務提供商（該術語在多倫多證券交易所風險投資交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。